COVID-19 Scan for Nov 20, 2020

News brief

Study details tracheal injuries in long-term ventilated COVID patients

A study yesterday found that 47% of COVID-19 patients who required prolonged mechanical ventilation developed potentially life-threatening tracheal (airway) complications.

The JAMA Otolaryngology Head & Neck Surgery study found that COVID-19 patients were significantly more likely to suffer full-thickness tracheal lesions (FTTL)—tears extending through the tracheal muscle wall—and tracheoesophageal fistulas (TEF)—an abnormal connection between a patient's airway and esophagus, which is the tube leading to the stomach.

Serious tracheal complications from prolonged mechanical ventilation are typically rare (0.3% to 3%), but caregivers have observed an unprecedented increase in patients with COVID-19, the study authors note.

The retrospective study compared 98 COVID-19 patients hospitalized in Pisa, Italy, for severe respiratory failure from Mar 1 to May 31, 2020, to a control group of 45 non-COVID-19 patients from Mar 1 to May 31, 2019. The mean age of patients in the COVID-19 group was similar to that of the control group (68.8 and 68.5 years, respectively).

In the COVID-19 group, 14 patients (47%) had FTTL or TEF as a result of intubation and prolonged ventilation, but only 1 patient (2.2%) in the control group developed FTTL (odds ratio [OR], 38.4; 95% confidence interval [CI]; 4.7 to 316.9).

The researchers suggest that a number of mechanisms may explain the incidence of tracheal injury, including early implementation of pronation maneuvers—placing patients on their stomach to facilitate ventilation—and the resulting increase in ventilation cuff pressure on tracheal walls, blood clotting complications in COVID-19 patients, viral weakening of tracheal tissues, steroid use, and caregiver fatigue contributing to accidents and mistakes.

The authors advocate for weekly bronchoscopy to detect tracheal lesions, cautious use of high-dose steroids, and careful monitoring of cuff pressure to prevent tracheal injury in ventilated COVID-19 patients.
Nov 19 JAMA Otolaryngol Head Neck Surg study

MMR vaccine may help prevent COVID-19

A small study today in mBio demonstrates that the measles, mumps, and rubella (MMR) vaccine may protect against COVID-19, as researchers found that levels of mumps immunoglobulin (Ig) G antibodies are inversely correlated with COVID-19 severity in MMR-vaccinated patients.

Epidemiologic data point to low COVID-19 death rates in populations with high MMR vaccination rates, but the mechanism of protection is still unclear. This study compared 50 MMR-vaccinated COVID-19 patients with a control group of 30 COVID-19 patients with no record of MMR vaccinations whose antibodies come primarily from previous measles, mumps, and rubella illness.

The researchers found a significant inverse correlation (-0.71, P < 0.001) between levels of mumps antibodies and COVID-19 severity in the MMR group. All asymptomatic and functionally immune patients had mumps titers—antibody levels—from 134 to 300 arbitrary units per milliliter (AU/ml). All 17 patients with mild COVID-19 symptoms had titers below 134 AU/ml, and 11 patients with moderate symptoms had titers below 75 AU/ml. All five hospitalized patients who required oxygen had titers below 32 AU/ml. No significant correlations were found between mumps titers and COVID-19 severity in the control group, or between disease severity and measles or rubella titers in either group.

"This adds to other associations demonstrating that the MMR vaccine may be protective against COVID-19, said lead study author Jeffrey E. Gold, president of World Organization, in a news release today from the American Society for Microbiology (ASM), which publishes mBio.

Older adults—including virtually all people born before 1957—likely have MMR antibodies from naturally acquired infections, but these antibodies may have waned by as much as 73% over time, the authors suggest. In addition, the researchers found that the mumps titer was the only MMR titer that steadily decreases over time (9.2% mean annual decay rate), leading to a mean titer of 142 AU/ml 9 years after vaccination.

"Based upon our study, it would be prudent to vaccinate those over 40 regardless of whether or not they already have high serum MMR titers," said coauthor David J. Hurley, PhD.
Nov 20 mBio study
Nov 20 ASM news release

Experts: COVID-19 vaccine distribution needs collaboration, transparency

For equitable COVID-19 vaccine distribution, the United States needs diverse clinical trial populations, data transparency—especially around emergency use authorization—universal accessibility, and collaboration, according to a five-point recommendation paper published in Health Affairs yesterday.

The vaccine experts add that the federal government must be transparent, timely, and consistent with its communications and guidelines, given that it sets underlying policies and decides on state grants.

The authors emphasize partnerships and coordination throughout their recommendations. Groups such as professional medical associations, AARP, and the NAACP can help ensure diverse populations are being included in trials, they say, and the Advisory Committee on Immunization Practices needs continued support from the National Academy of Science, Engineering and Medicine and the National Association of Medicine as it formulates distribution plans.

While federal agencies and departments may be working with McKesson, state and local organizations will be needed to get the vaccine to people. The article points to the unique vaccination sites and partners used in the H1N1 pandemic flu vaccine distribution in 2009 and 2010 as an example of how the traditional supply chain was modified to make sure pregnant women, high-risk adults, and children didn't slip through the cracks.

An estimated 20% of the US population may be completely uninsured, according to the authors, so they recommend more funding to reach those populations.

To help track coverage, the immunization information systems (IIS) should have an opt-out policy and share data across state borders, the experts say. All vaccine administrators ought to help with this, including school nurses, health insurance providers, and Medicaid providers, they add. Currently, the authors say, children and teens have 95% and 80% representation, respectively, in the IIS, but only about 56% adults are documented within the system.
Nov 19 Health Aff study
Nov 19 Children's Hospital of Philadelphia press release

News Scan for Nov 20, 2020

News brief

CWD confirmed in 2 Minnesota deer, bringing 2020 total to 16

Two deer recently tested positive for chronic wasting disease (CWD), reports the Minnesota Department of Natural Resources (DNR), bringing the state's 2020 cases to 16 and total cases to 95.

Last year saw 44 deer test positive, a 158.8% jump from 2018's 17 cases. CWD is a fatal neurologic disease with no known cure that transfers from cervids such as deer, elk, and moose to other cervids through prions in saliva, urine, blood, feces, antler velvet, and carcasses.

One deer was an adult male harvested Nov 7 in Dakota County, the first hunter-harvested one to test positive in the new south metro disease management zone. The other was hit by a vehicle in the southeast metro disease management zone in Olmsted County on Nov 4. While the latter was not the first deer to test positive within deer permit area 643, this is the farthest northwest a case has been found in that zone.

While hunter-harvested deer sampling is voluntary across the state this year because of COVID-19 precautions, the DNR urges hunters in disease management and surveillance zones to bring samples of deer over 1 year old to designated drop-off stations. Not only does this help track CWD spread, but if the deer is positive, then the DNR can help facilitate safe disposal of the meat and carcass.

Since CWD was first detected in 2002, the DNR has tested more than 90,000 wild deer in the state.
Nov 19 Minnesota DNR notice

Countries in Middle East, Africa report more polio cases

Six countries reported new polio cases over the past week, two in the Middle East and four in Africa, according to the latest weekly update from the Global Polio Eradication Initiative (GPEI).

In the Middle East, Afghanistan reported 1 more wild poliovirus type 1 (WPV1) case, a patient from Kandahar province, raising its total for 2020 to 54. Neighboring Pakistan also reported a WPV1 case, which involved a patient from Punjab province, raising its total to 81 for the year. It also reported 3 more circulating vaccine-derived poliovirus type 2 (cVDPV2) cases, 2 in Sindh province and 1 in Punjab province, putting the country's total at 83 for the year.

In Africa, Burkina Faso reported 5 cVDPV2 cases in four different provinces, boosting its total for 2020 to 45 from two different outbreaks. The Democratic Republic of the Congo reported 3 more such cases, 2 in Maindombe province and 1 in Equateur province, pushing its number for 2020 to 63 so far.

Nigeria reported one more cVDPV2 case, in Sokoto state, which raised the country's total this year to four. And finally, Sudan reported 5 more cVDPV2 cases in four provinces, making 44 for 2020.
Nov 19 GPEI update

ASP Scan (Weekly) for Nov 20, 2020

News brief

Our weekly wrap-up of antimicrobial stewardship & antimicrobial resistance scans

Report says COVID-19 holds lessons for response to AMR

Originally published by CIDRAP News Nov 19

The COVID-19 pandemic, and the global response, contain important lessons that can be used to avert a future pandemic caused by antimicrobial resistance (AMR), according to a new report from the Global Antibiotic Research and Development Partnership (GARDP).

The report notes that while there are differences between fast-moving viral pandemics and the slower-moving "silent pandemic" of AMR, the COVID-19 pandemic has underscored what happens when governments are unprepared, international cooperation is low, and treatments, diagnostics, and vaccines are not available. As a result, the pandemic is reinforcing the importance of research, development, and equitable supply of medical countermeasures to treat and prevent pandemic diseases and presenting an opportunity to improve the response to future pandemics, including those caused by drug-resistant infections, the authors say.

Among the lessons highlighted in the report are that investments in preparedness are necessary, collaboration and international cooperation are critical, and that equitable and affordable access to medical countermeasures is an essential element of effective pandemic response. But inequitable access to medical countermeasures can undermine the trust that many nations have in the international system.

To prepare for a pandemic of drug-resistant infections, the report recommends five concrete steps that the global community can take. These include recognizing and addressing antibiotic resistance; investing in development of medical countermeasures; ensuring that access to treatments, diagnostics, and vaccines for all is a cornerstone of pandemic preparedness and response; expanding global cooperation within a One Health framework; and making low- and middle-income countries equal partners in a comprehensive response.

"AMR requires a long-term investment and is an opportunity for governments to find a collective approach to global health that is fair to all; that prioritises coordination, partnership and solidarity; that takes a multisectoral and multilateral approach; and that satisfies public health needs and human life over economic and political considerations," the report concludes. "Achieving this would cascade into lasting and life-saving benefits for people and countries across the world."
Nov 17 GARDP report

UK farmers, veterinarians set new targets for antibiotic use in animals

Originally published by CIDRAP News Nov 19

A task force of veterinarians and farmers in the United Kingdom yesterday released new targets for responsible use of antibiotics in farm animals.

The goals for 2021 through 2024, laid out in a report from the Responsible Use of Medicines in Agriculture Alliance (RUMA), include a 30% decrease in antibiotic use in pigs, reductions of 15% in dairy herds and 25% in calf rearing units, and a 40% reduction in game birds.

"We look forward to working with the sectors as we continue on this endeavour, which will ultimately be of benefit to the reputation of the UK livestock sectors as well as helping to protect human and animal health," Peter Borriello, PhD, chief executive of the UK's Veterinary Medicines Directorate, said in a RUMA press release.

The new goals were released the same day as the UK Veterinary Antibiotic Resistance and Sales Surveillance Report (UK-VARSS 2019), which showed a 45% decline in sales of antibiotics for food-producing animals from 2015 through 2019 (despite a 5% increase between 2018 and 2019), and 74% decline in the sales of highest-priority critically important antibiotics. The report also showed lower levels of antibiotic resistance in Escherichia coli in healthy pigs at slaughter compared with 5 years ago.

RUMA says its initial targets, released in 2017, have helped UK farmers achieve the antibiotic sales reductions documented in the UK-VARSS report. Over 75% of the 2017 targets have already been achieved or are on track to be achieved by December.

"The UK farming industry has responded extremely well to the targets. Our original aim of lowering overall antibiotic use, and in particular highest-priority critically important antibiotics (HP-CIAs), has been categorically achieved in the face of some challenging external conditions," said RUMA chair Catherine McLaughlin.
Nov 18 RUMA press release
Nov 18 RUMA 2020 targets task force report
Nov 18 UK-VARSS 2019 report

UK reports show rise in resistant infections, drop in gonorrhea resistance

Originally published by CIDRAP News Nov 19

Two reports released yesterday by Public Health England (PHE) highlight good and bad news on antibiotic-resistant infections in humans.

The English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR) report shows a 17% increase in incidence of bloodstream infections caused by key bacterial species (E coli, Klebsiella pneumoniae, Enterococcus spp) between 2015 and 2019 and a 32% increase in antibiotic-resistant bloodstream infections caused by those species, with an estimated 18,110 antibiotic-resistant bloodstream infections diagnosed in England in 2019 (up from 13,671 in 2015). Overall, the report estimates there were 65,162 severe antibiotic-resistant infections diagnosed in 2019, up from 61,946 in 2018.

But the report also shows that antibiotic consumption in England has fallen since peaking in 2014, with total use declining from 19.4 defined daily doses per 1,000 inhabitants per day in 2015 to 17.4 in 2019, driven largely by a 12.2% decline in antibiotic prescribing in general practices and a 19.5% decline in dental practices. Antibiotic consumption rose, however, in other community settings and in hospital inpatients and outpatients.

The report from the Gonococcal Resistance to Antimicrobial Surveillance Programme (GRASP), meanwhile, found that the proportion of Neisseria gonorrhoeae isolates in England and Wales with reduced susceptibility to ceftriaxone—the current first-line therapy for gonorrhea in England—fell from 7.1% in 2018 to 2.9% in 2019, following a steady increase from 2013 through 2018. Outside of the sentinel surveillance system, three cases of ceftriaxone-resistant gonorrhea were confirmed by PHE in 2019.

The surveillance report also showed a slight decline in azithromycin resistance (9.8% to 9.3%) and a decline in cefixime resistance (2.2% to 0.8%).

"The effectiveness of first-line treatment for gonorrhoea continues to be threatened by the development of antimicrobial resistance," the report said. "However, the decline in reduced ceftriaxone susceptibility, together with decreasing cefixime resistance and stable rates of azithromycin resistance, are encouraging developments."
Nov 18 PHE ESPAUR report
Nov 18 PHE GRASP report

CARB-X to fund development of monoclonal antibody for biofilm infections

Originally published by CIDRAP News Nov 18

CARB-X announced today that it is awarding up to $2.42 million to Clarametyx Biosciences of Columbus, Ohio, to develop a monoclonal antibody treatment for serious infections caused by bacterial biofilms.

The money from CARB-X (the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator) will help fund preclinical development of CMTX-101, a monoclonal antibody designed to rapidly collapse bacterial biofilms by targeting a region of DNABII-binding proteins that help stabilize and maintain biofilm integrity.

Biofilms are communities of microbes that can grow on medical devices and human tissue and form a protective layer around bacteria. They are highly resistant to antibiotics and the immune system and are therefore difficult to treat.

"Bacterial biofilms are a serious global health concern due to their ability to resist both antibiotics and the host’s immune system," Erin Duffy, PhD, director of research and development at CARB-X, said in a press release. "We urgently need new therapeutics to address life-threatening bacterial infections. Clarametyx is developing an exciting new approach that could be effective against a broad range of serious drug-resistant pathogens and also numerous types of infections."

Clarametyx will be eligible for an additional $11.85 million if it meets project milestones.

Since launching in 2016, CARB-X has awarded more than $259 million to 73 projects focused on antibiotic-resistant bacteria.
Nov 18 CARB-X press release

Study links COVID restrictions to increased UK dental antibiotic use

Originally published by CIDRAP News Nov 17

A study published late last week in the British Dental Journal suggests that restricted access to dental care in England during the early months of the COVID-19 pandemic resulted in a sharp rise in dental antibiotic prescribing.

In the study, researchers from the National Health Service (NHS) and the University of Manchester analyzed NHS data on dental antibiotic prescriptions dispensed by community pharmacists from January 2018 to July 2020. They aimed to describe trends in overall dental antibiotic use across England during that period and compare trends in the rate of use between the seven NHS England regions from April 2020, when COVID-19 restrictions were first put in place and dental practices were restricted to providing remote management of patients, to July 2020.

The results showed a downward trend in the number of antibiotic prescriptions dispensed to NHS dental patients up until March 2020, followed by a sharp upward trend that started in April 2020 and plateaued in July 2020 after dental practices were allowed to reopen. Compared to April to July 2019, dental antibiotic prescribing was 25% higher in April to July 2020. All areas of the country saw increases in prescribing in May and June, with the highest increase in London (60%) and lowest in the South West of England (10%). Overall, the highest rate of antibiotic dispensing to NHS dental patients occurred in the East of England in June (6.1 antibiotic prescriptions per 1,000 population).

The study was released on the same day as a white paper from FDI World Dental Federation that highlights how dental teams can help raise awareness, prevent and control infections, and optimize the use of antibiotics to help tackle the problem of antibiotic resistance.

"Patients waiting for access to care often receive more antibiotics than those patients who receive the right treatment immediately," study and white paper lead author Wendy Thompson, PhD, of the University of Manchester, said in a press release. "As dental care provision returns to a 'new normal' in the COVID-19 era, it is important to ensure access to high-quality, urgent dental care and to optimize the use of antibiotics."
Nov 13 Br Dent J study
Nov 13 FDI World Dental Federation white paper
Nov 13 FDI World Dental Federation press release

Reports cites gaps in TB diagnosis, prevention, and treatment

Originally published by CIDRAP News Nov 17

A report published yesterday by the Stop TB Partnership and Médecins Sans Frontières highlights policy gaps that the two groups say are undermining progress in the fight against tuberculosis (TB), including drug-resistant (DR)-TB.

The Step Up for TB 2020 report, which examines the national TB policies of 37 high-burden countries and assesses the extent to which they align with World Health Organization (WHO) guidelines and recommendations, finds that many of the countries have outdated diagnostic, treatment, and prevention policies. For example, while more than 80% indicate they are able to use rapid molecular tests as the initial diagnostic test for TB, many countries have not implemented this policy at scale, and less than a quarter of the countries offer a comprehensive set of drug susceptibility testing methods to ensure TB patients aren't being treated with drugs against which their bacteria are resistant.

On treatment, the report finds that only 61% of countries are using the modified, shorter all-oral treatment for DR-TB recommended by the WHO, while nearly half are still using regimens containing the most toxic injectable medicines. Only 65% of countries have policies for the type of shorter TB preventive treatment that can help reduce the number of latent TB infections that develop into active infections, and only half of the countries surveyed screen household members of people who have TB.

"Earlier this year, the COVID-19 pandemic hit the world with devastating impact, and governments around the world quickly adopted new policies and laws in response," Lucica Ditiu, MD, executive director of the Stop TB Partnership, said in a press release. "Meanwhile, TB remains the top infectious disease killer, even though it is preventable and curable. To make matters worse, most countries still use outdated policies, practices, tools and treatment regimens."

The report calls for countries to make relevant policy reforms a central part of their national TB response to meet the United Nations 2022 TB targets. Among those targets are diagnosis and treatment of 40 million people who have active TB and 30 million who have latent TB infection.
Nov 16 Stop TB Partnership press release
Nov 16 Step Up for TB 2020 report